Recent Data on Axi-Cel in Lymphoma
Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.
Source: onclive.com
Mash 2023 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mash 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mash 2023 Today - Breaking & Trending Today
Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma
Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.
Source: onclive.com
Challenges in Managing Adverse Events and Unmet Needs in Leukemia
Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.
Source: onclive.com
Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Source: onclive.com
Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL
Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.
Source: onclive.com